Evogene Ltd. (TLV:EVGN)

Market Cap	16.19M -54.7%
Revenue (ttm)	5.82M -72.7%
Net Income	-37.16M
EPS	-4.32
Shares Out	10.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,424
Open	155.50
Previous Close	155.50
Day's Range	143.60 - 155.50
52-Week Range	115.10 - 478.70
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 52
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error